Imaging of brain tumors after administration of L-(N-13)glutamate: concise communication.
Cyclotron-produced L-(N-13)glutamate was used to visualize malignant intracranial tumors in 12 pediatric patients who had evidence of recurrent disease as documented by computed transaxial tomography (TCT). Imaging was performed using a rectilinear scanner, gamma camera, or a positron-emission tomograph (PET). The results indicate that N-13 is rapidly taken up by a majority of brain tumors following the administration of L-(N-13)glutamate, and that N-13 uptake is correlated with breakdown of the blood-brain barrier as demonstrated by contrast TCT or pertechnetate (Tc-99m) studies. The feasibility of using this agent in conjunction with PET is established.
D000293:Adolescent; D000328:Adult; D001812:Blood-Brain Barrier; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D002648:Child; D005260:Female; D005971:Glutamates; D018698:Glutamic Acid; D006801:Humans; D008297:Male; D009590:Nitrogen Radioisotopes; D013670:Sodium Pertechnetate Tc 99m; D013667:Technetium; D014055:Tomography, Emission-Computed / Q000379:methods*; D014057:Tomography, X-Ray Computed
D005971:Glutamates; D009590:Nitrogen Radioisotopes; D018698:Glutamic Acid; D013667:Technetium; D013670:Sodium Pertechnetate Tc 99m